Currently out of the existing stock ratings of Matthew Andrews, 22 are a BUY (91.67%), 2 are a HOLD (8.33%).

Matthew Andrews

Work Performance Price Targets & Ratings Chart

Analyst Matthew Andrews works with a stock forecast success ratio of 68.06% fulfilled within 224.67 days on average. Previously, Matthew Andrews worked at JEFFERIES.

Matthew Andrews’s has documented 47 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SPPI, Spectrum Pharmaceuticals at 06-Sep-2018.

Wall Street Analyst Matthew Andrews

Analyst best performing recommendations are on NRBO (NEUROBO PHARMACEUTICALS).
The best stock recommendation documented was for NRBO (NEUROBO PHARMACEUTICALS) at 8/13/2018. The price target of $9000 was fulfilled within 2 days with a profit of $960 (9.64%) receiving and performance score of 48.19.

Average potential price target upside

GEMP Gemphire Therapeutics IMMU Immunomedics NRBO Neurobo Pharmaceuticals TXMD TherapeuticsMD SPPI Spectrum Pharmaceuticals VNDA Vanda Pharmaceuticals

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

2

$-5.5 (-73.33%)

18

5 years 6 months 9 days ago

3/4 (75%)

$0.34 (20.48%)

130

Hold

2

$-5.5 (-73.33%)

30

5 years 6 months 12 days ago

1/3 (33.33%)

$14.2 (165.52%)

27

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Matthew Andrews?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?